For adults with overweight or obesity without diabetes, glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are efficacious ...

For this review, the authors searched for randomized controlled trials published in MEDLINE, Embase, and Cochrane CENTRAL ...

A nationwide study confirms GLP-1 RAs pose no short-term psychiatric risk, showing a negative association with suicidal ...

Research showed that patients who lose weight on GLP-1 agonists frequently experience muscle mass loss. Obesity experts share ...

A systematic review of randomized controlled trials (RCTs) assessed the efficacy and safety of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and co-agonists for obesity in adults without ...

These drugs, called glucagon-like peptide-1 receptor agonists (GLP-1 RAs), work in several different ways to help people lose ...

Weight loss tops many folks' list of New Year's resolutions, and lots of people are turning to cutting-edge weight-loss drugs ...

Intuitively, it would seem that GLP-1 use for obesity would reduce overall medical costs despite the increase in drug ...

New in vivo preclinical data announced today, demonstrate that icovamenib, in combination with semaglutide showed additional 11.5% body weight ...

Professor Choi Hyung-jin of Seoul National University, who identified the exact mechanism by which obesity treatment ...

Other approaches that are in development include fibroblast growth factor (FGF) mimetics such as FGF21-targeting candidates ...